Cardiovascular Systems presented one-year data and a new economic analysis from its ORBIT II coronary study in a late-breaker session at the Society for Cardiovascular Angiography and Interventions (SCAI) 2014 conference (28–31May; Las Vegas, USA). The ORBIT II study of the company’s Diamondback 360 coronary orbital atherectomy system evaluated the safety and effectiveness of Cardiovascular Systems’ technology in treating severely calcified lesions in coronary arteries.
Jeffrey Chambers of the Metropolitan Heart and Vascular Institute, Minneapolis, USA, presented one-year data that demonstrate freedom from target lesion revascularisation and target vessel revascularisation of 95% and 98%, respectively. The ORBIT II study also reported freedom from cardiac death of 97%.
Additionally, a key economic analysis by economist Louis Garrison, Jr, University of Washington, Seattle, USA, was presented. Data showed that patients treated with the Diamondback 360 coronary orbital atherectomy system in the ORBIT II study have been associated with shorter hospital stays and lower retreatment rates, compared to Medicare patients treated with traditional technologies, resulting in an average lower cost of US$3,200 per patient.
The Medicare comparison sample was drawn from the 100% Standard Analytical File for the period September 2011 through December 2012. This data, presented for the first time at SCAI 2014, builds on a previous ORBIT II economic analysis by including a larger investigation of ORBIT II subjects and both outpatient and inpatient data, versus in-patient analysis only.
“This ORBIT II data demonstrates that the orbital atherectomy system from Cardiovascular Systems provides one-year durable results, while giving physicians a cost effective way to address coronary calcium in these difficult-to-treat patients,” said Chambers.